What is it about?
In this pre-clinical study, we developed a novel approach (XDeath) by computational technology to screen new potential therapeutic targets for prostate cancer treatment. Interestingly, we identified a novel co-target, Plk1 and DNMT3a and validated the efficacy of co-inhibition of these two targets preclinically. The results showed that co-inhibition of Plk1 and DNMT3a significantly inhibited prostate cancer, providing evidence for translational study in clinic in the future.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
A novel bioinformatic tool, XDeath was developed and applied to identify the novel targets for advanced prostate cancer for the first time. Subsequent series of experiments proved the promising of the combination treatments targeting Plk1 and DNMT3a pre-clinically. This study for the first time translates the findings generated by bioinformatics to pre-clinical studies and finally possibly in clinic.
Perspectives
I hope this article makes what people might think is a boring, slightly abstract area like therapeutic targets mining, kind of interesting and maybe even exciting. Because the way we spend money on health is not just a problem for politicians, managers and researchers to worry about - it is an issue that touches every single human being on this planet in one way or another. More than anything else, and if nothing else, I hope you find this article thought-provoking.
Zhuangzhuang Zhang
University of Kentucky
Read the Original
This page is a summary of: Co‐Targeting Plk1 and DNMT3a in Advanced Prostate Cancer, Advanced Science, May 2021, Wiley,
DOI: 10.1002/advs.202101458.
You can read the full text:
Contributors
The following have contributed to this page
